Breast Cancer | Specialty

FDA Provides Update on Breast Implant–Associated Lymphoma, Illness

August 25th 2020

The FDA has provided an update on breast implant-associated adverse effects, such as breast implant-associated anaplastic large cell lymphoma and breast implant illness.

Tesetaxel Plus Reduced-Dose Capecitabine Significantly Prolongs PFS in Metastatic Breast Cancer

August 24th 2020

Tesetaxel in combination with a reduced dose of capecitabine led to a significant improvement in progression-free survival versus the approved dose of capecitabine alone, meeting the primary end point of the phase 3 CONTESSA trial.

Dr. Mamounas on the Role of Extended Adjuvant Endocrine Therapy in ER+ Breast Cancer

August 24th 2020

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the role of extended adjuvant endocrine receptor–positive breast cancer.

Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era

August 24th 2020

In our exclusive interview, Dr. Meisel and Dr. Hamilton provided insight on key data from the 2020 ASCO Virtual Scientific Program and best practices in managing patients during the coronavirus disease 2019 pandemic.

Expert Perspectives on the Identification and Management of Drug-Induced Interstitial Lung Disease

August 24th 2020

Experts share insight on their clinical experience with interstitial lung disease.

Overview and Management of Drug-Induced Interstitial Lung Disease With Novel Treatments in HER2+ Breast Cancer, Lung Cancers, and Gastrointestinal Cancers

August 22nd 2020

Recently developed treatments for HER2-positive breast cancer, lung cancers, and gastrointestinal cancers include antibody-drug conjugates, CDK4/6 inhibitors, and immuno-oncology agents.

Dr. Burris on the Utility of Sacituzumab Govitecan in Metastatic TNBC

August 21st 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​the utility of sacituzumab govitecan-hzi​y in metastatic triple-negative breast cancer.

Dr. Yardley on Challenges With Resistance Mechanisms in HR+/HER2- Breast Cancer

August 19th 2020

Denise Yardley, MD, discusses challenges with ​resistance mechanisms in hormone receptor–positive, HER2-negative breast cancer. 

Tripathy Navigates Ever-Changing HER2+ Breast Cancer Treatment Landscape

August 19th 2020

Debu Tripathy, MD, discusses tucatinib and fam-trastuzumab deruxtecan-nxki as 2 exciting drug approvals in the constantly changing HER2-positive breast cancer treatment paradigm.

Presence of ctDNA, CTCs Independently Linked With Early-Stage TNBC Recurrence

August 19th 2020

A new, recently patented liquid biopsy device designed to detect small amounts of genetic and cellular material from tumors in the bloodstream of patients with early-stage, recurrent triple negative breast cancer, following neoadjuvant chemotherapy, has shown great accuracy and sensitivity.

Dr. Hamilton on the Promise of Tucatinib in HER2+ Breast Cancer Brain Metastases

August 18th 2020

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

Dr. O’Shaughnessy on the Utility of Tucatinib in the HER2+ Breast Cancer Brain Metastases

August 18th 2020

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

August 18th 2020

Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Dr. Yardley on Endocrine Therapy Plus CDK4/6 Inhibitors in Breast Cancer With Visceral Metastases

August 17th 2020

Denise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

Pegram Unpacks Pivotal Data in Breast Cancer

August 17th 2020

In our exclusive interview, Dr. Pegram discusses the unique structure of trastuzumab deruxtecan, initial and subset analyses from the DESTINY-Breast01 trial, potential adverse effects, and recommended management strategies for the agent.

Antibody-Drug Conjugates in HER2-Positive Breast Cancer

August 14th 2020

Novel antibody-drug conjugates introduce promising options for the management of patients with HER2-positive breast cancer; however, management of drug-related toxicities and optimal sequencing of HER2-targeted therapies remains an ongoing challenge.

Dr. O'Regan on Emerging CDK4/6 Combinations in Breast Cancer

August 14th 2020

Ruth O’Regan, MD, discusses emerging CDK4/6 inhibitor combinations in breast cancer.

Adjuvant T-DM1 Shows Consistent Benefit in Residual Invasive HER2+ Breast Cancer, Irrespective of Mutational Status

August 14th 2020

Ado-trastuzumab emtansine demonstrated a consistent invasive disease-free survival benefit versus trastuzumab in patients with HER2-positive breast cancer across all biomarker subgroups evaluated in the pivotal phase 3 KATHERINE trial.

Dr. Han on the Importance of pCR in Breast Cancer

August 13th 2020

Heather ​S. Han, MD, discusses the importance of pathologic complete response in breast cancer.

Perioperative Therapy: ASCO 2020 Data Updates

August 13th 2020